Population-based analysis of a novel prognostic model for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA).

被引：2
|
作者：
Azad, Arun
Lester, Renee
Leibowitz-Amit, Raya
Joshua, Anthony M.
Heng, Daniel Yick Chin
Eigl, Bernhard J.
Chi, Kim N.
机构：
[1] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[2] Tom Baker Canc Clin, Calgary, AB, Canada
[3] Univ Toronto, Div Med Oncol, Princess Margaret Hosp, Toronto, ON, Canada
[4] Princess Margaret Hosp, Univ Hlth Network, Toronto, ON M4X 1K9, Canada
[5] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada
[6] Canc Agcy, Vancouver, BC, Canada
[7] BC Canc Agcy, Vancouver Canc Ctr, Vancouver, BC, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.5078
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5078
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Population-based analysis of a novel prognostic model for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA)
    Azad, Arun
    Lester, Renee
    Leibowitz-Amit, Raya
    Joshua, Anthony Michael
    Heng, Daniel Yick Chin
    Eigl, Bernhard J.
    Chi, Kim N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [2] Assessment of prognostic factors in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA) after docetaxel (DOC).
    Cavaliere, Carla
    Caffo, Orazio
    Ortega, Cinzia
    D'aniello, Carmine
    Di Napoli, Marilena
    Cecere, Sabrina Chiara
    Della Pepa, Chiara
    Crispo, Anna
    Maines, Francesca
    Ruatta, Fiorella
    Iovane, Gelsomina
    Montella, Maurizio
    Pignata, Sandro
    Facchini, Gaetano
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] A multicenter population-based experience with abiraterone acetate (AA) in patients with metastatic castration resistant prostate cancer (mCRPC)
    Clayton, Ravinder
    Heng, Daniel Yick Chin
    Wu, Jackson S. Y.
    Zielinski, Rob
    North, Scott A.
    Emmenegger, Urban
    Hotte, Sebastien J.
    Al-Shamsi, Humaid Obaid
    Chen, Leo
    Eigl, Bernhard J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [4] A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel.
    Chi, Kim N.
    San Kheoh, Thian
    Ryan, Charles J.
    Molina, Arturo
    Bellmunt, Joaquim
    Vogelzang, Nicholas J.
    Rathkopf, Dana E.
    Fizazi, Karim
    Kantoff, Philip W.
    Li, Jinhui
    De Bono, Johann Sebastian
    Scher, Howard I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone acetate (AA)
    Rathkopf, Dana E.
    Antonarakis, Emmanuel S.
    Shore, Neal D.
    Tutrone, Ronald
    Alumkal, Joshi J.
    Ryan, Charles J.
    Saleh, Mansoor N.
    Hauke, Ralph J.
    Bandekar, Rajesh
    Maneval, Edna Chow
    de Boer, Carla
    Todd, Mary
    Yu, Margaret K.
    Scher, Howard I.
    [J]. CANCER RESEARCH, 2014, 74 (19)
  • [6] Prognostic index model (PIM) for overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy treated with abiraterone acetate (AA).
    Ryan, Charles J.
    Kheoh, Thian
    Li, Jinhui
    Molina, Arturo
    De Porre, Peter
    Carles, Joan
    Efstathiou, Eleni
    Kantoff, Philip W.
    Mulders, Peter F. A.
    Saad, Fred
    Griffin, Thomas W.
    Chi, Kim N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] Potential prognostic and predictive factors in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) in daily clinical practice in Spain.
    Celiz, Pamela
    Pinto, Alvaro
    Puente, Javier
    Manneh, Ray
    Gonzalez Larriba, Jose Luis
    Grande, Enrique
    Alonso, Teresa
    Manuel Sepulveda, Juan
    Rodriguez, Alfredo
    Castellano, Daniel E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Evaluating the safety of abiraterone acetate (AA) and docetaxel (D) administered in combination in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Tagawa, Scott T.
    Nanus, David M.
    Posadas, Edwin M.
    Petrylak, Daniel Peter
    Bruce, Justine Yang
    Lim, Emerson A.
    Peng, Weimin
    Maul, Raymond Scott
    Gonzalez, Martha
    Tran, Namphuong
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [9] EXPLORATORY ANALYSIS OF THE SAFETY PROFILE OF ABIRATERONE ACETATE (AA) IN PATIENTS (PTS) RECEIVING CONCOMITANT RADIATION THERAPY IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
    Saad, Fred
    Molina, Arturo
    Li, Justin
    Thian Kheoh
    Scher, Howard I.
    [J]. JOURNAL OF UROLOGY, 2012, 187 (04): : E278 - E278
  • [10] Phase 1b study of abiraterone acetate (AA) and docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Tagawa, Scott T.
    Posadas, Edwin M.
    Bruce, Justine Yang
    Lim, Emerson A.
    Petrylak, Daniel Peter
    Peng, Weimin
    Maul, Raymond Scott
    Smit, Hans W.
    Tran, Namphuong
    Nanus, David M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345